BioNTech SE reported fourth‑quarter 2025 results on March 10, 2026, with total revenue of €907.4 million and a net loss of €0.38 per share. The revenue figure exceeded consensus estimates of €784.3 million, marking a beat of €123.1 million. The loss, however, was larger than some analysts’ expectations of a €0.19 loss per share, indicating a miss on earnings per share.
The revenue beat was driven by continued demand for the company’s core vaccine and oncology products, but was partially offset by a decline in COVID‑19 vaccine sales as global demand normalizes. A significant upfront payment of $1.5 billion from the partnership with Bristol Myers Squibb was recognized in the third quarter of 2025, not in the fourth quarter, and helped support the company’s cash position but did not contribute to the Q4 earnings figure.
The earnings miss can be attributed to the timing of the BMS payment and the company’s ongoing investment in its oncology pipeline, which increased research and development expenses. The loss per share was also influenced by one‑time charges related to restructuring and other non‑recurring items that were not fully offset by the BMS payment in Q4.
For the full year 2026, BioNTech guided for revenue of €2.0 billion to €2.3 billion, a range that is below analyst expectations of €3.12 billion. The guidance reflects management’s view that COVID‑19 vaccine demand will continue to decline, while the company focuses on expanding its oncology portfolio. The guidance was issued in euros, not dollars, and represents a cautious outlook for the coming year.
CEO Prof. Ugur Sahin said, "2025 was a year of strong execution and pipeline momentum, marked by substantial progress in delivering on our strategy. We advanced our oncology pipeline by moving multiple programs into late‑stage development and initiated trials assessing novel‑novel combination approaches with the aim of delivering differentiated therapeutic profiles." CFO Ramón Zapata added, "We expect total revenues for 2026 in the range of EUR 2 billion to EUR 2.3 billion."
Investors reacted negatively to the earnings release, citing the lower‑than‑expected 2026 revenue guidance and the announcement that co‑founders Ugur Sahin and Özlem Türeci plan to establish an independent company focused on next‑generation mRNA innovations by the end of 2026. These developments raised concerns about leadership continuity and the company’s future growth trajectory.
Comparing to prior periods, Q4 2024 revenue was €1.19 billion with an earnings per share of $1.08, while Q3 2025 revenue was €1.52 billion and a net loss of €0.12 per share. The current quarter’s revenue decline and loss per share highlight a deceleration in the company’s legacy vaccine business as it pivots toward oncology.
BioNTech’s strong cash position of €17.2 billion provides a solid foundation for continued investment in its oncology pipeline, including the BNT327 bispecific antibody. The company’s strategic shift toward oncology, coupled with its robust cash reserves, positions it to pursue growth opportunities in a high‑barrier therapeutic area while managing the transition away from pandemic‑era vaccine revenue.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.